These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26077516)

  • 21. Short communication: emerging transmitted HIV type 1 drug resistance mutations among patients prior to start of first-line antiretroviral therapy in middle and low prevalence sites in China.
    Wang X; He C; Xing H; Liao L; Xu X; He J; Liu Y; Ling H; Liang S; Hsi JH; Ruan Y; Shao Y
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1637-9. PubMed ID: 22822770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
    Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
    Ibe S; Sugiura W
    Future Microbiol; 2011 Mar; 6(3):295-315. PubMed ID: 21449841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Diversity and Drug Resistance Among Antiretroviral Treatment-Failed Individuals from 2010 to 2012 in Honghe, China.
    Yang C; Yang S; Li J; Yang B; Liu J; Li H; Bian Z
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):822-9. PubMed ID: 25919896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in the reverse transcriptase and protease genes of human immunodeficiency virus-1 from antiretroviral naïve and treated pediatric patients.
    Bure D; Makhdoomi MA; Lodha R; Prakash SS; Kumar R; Parray HA; Singh R; Kabra SK; Luthra K
    Viruses; 2015 Feb; 7(2):590-603. PubMed ID: 25674767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
    Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug resistance mutations and its associated factors among 579 HIV/AIDS patients experiencing failure of antiretroviral therapy in Jiangsu Province, China].
    Xiao PP; Lu J; Hu HY; Xu XQ; Ding P; Fu GF; Huan XP; Zhou Y; Yang HT
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Nov; 51(11):988-993. PubMed ID: 29136743
    [No Abstract]   [Full Text] [Related]  

  • 34. [Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China].
    Si XF; Huang HL; Wei M; Guan Q; Song YH; Ma PF; Quan Y; Xing H; Shao YM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Dec; 18(4):308-11. PubMed ID: 15650776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.
    Li H; Zhong M; Guo W; Zhuang D; Li L; Liu Y; Bao Z; Liu S; Wang X; Li T; Yang S; Li J
    PLoS One; 2013; 8(8):e72630. PubMed ID: 24009694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C
    Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
    de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
    Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
    Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
    J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.